FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 104 filers reported holding FATE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,972,000 | +26.1% | 202,000 | -21.1% | 0.02% | +23.5% |
| Q4 2017 | $1,564,000 | +54.2% | 256,000 | 0.0% | 0.02% | +41.7% |
| Q3 2017 | $1,014,000 | +25.2% | 256,000 | +2.4% | 0.01% | +20.0% |
| Q2 2017 | $810,000 | -28.8% | 250,000 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $1,138,000 | +81.2% | 250,000 | 0.0% | 0.01% | +75.0% |
| Q4 2016 | $628,000 | -19.5% | 250,000 | 0.0% | 0.01% | -33.3% |
| Q3 2016 | $780,000 | +16.2% | 250,000 | -36.6% | 0.01% | +20.0% |
| Q2 2016 | $671,000 | -21.4% | 394,537 | -16.9% | 0.01% | -28.6% |
| Q1 2016 | $854,000 | +12.8% | 474,537 | +111.3% | 0.01% | 0.0% |
| Q4 2015 | $757,000 | +50.5% | 224,537 | +137.8% | 0.01% | +27.3% |
| Q3 2015 | $503,000 | +110.5% | 94,437 | +155.2% | 0.01% | +120.0% |
| Q2 2015 | $239,000 | – | 37,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |